Cognition Therapeutics Inc - ESG Rating & Company Profile powered by AI
This webpage contains a zero-cost ESG assessment for Cognition Therapeutics Inc. This analysis of Cognition Therapeutics Inc is assembled by All Street Sevva using advanced AI. The webpage includes a questions and answers section for Cognition Therapeutics Inc.
Cognition Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.3; made up of an environmental score of 0.0, social score of 0.0 and governance score of 4.0.
1.3
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1747 | Sinphar Pharmaceutical Co Ltd | 1.4 | Low |
1747 | WooGene B&G Co Ltd | 1.4 | Low |
1755 | Cognition Therapeutics Inc | 1.3 | Low |
1755 | Cheng Du Sheng Nuo Biotec Co Ltd | 1.3 | Low |
1755 | ALX Oncology Holdings Inc | 1.3 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |
Frequently Asked Questions
Does Cognition Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Cognition Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Cognition Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Cognition Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Cognition Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Cognition Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Cognition Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Cognition Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Cognition Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Cognition Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Cognition Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Cognition Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Cognition Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Cognition Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Cognition Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Cognition Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Cognition Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Cognition Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Cognition Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Cognition Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Cognition Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Cognition Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Cognition Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Cognition Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Cognition Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Cognition Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Cognition Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Cognition Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Cognition Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Cognition Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Cognition Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Cognition Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Cognition Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Cognition Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Cognition Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Cognition Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Cognition Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.